Meridian Bioscience Expands Production Capacity in Ohio

Meridian’s expansion will help with manufacturing of COVID-19 testing components

Posted on February 16, 2021May 25, 2021

Company Name: Meridian Bioscience, Inc.
Location: Newtown
Industry Sector: Healthcare
Company Profile: Meridian Bioscience, Inc. (NASDAQ: VIVO) is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.
Company Website: www.meridianbioscience.com

Project Summary:

Type of Project: Expansion
Capital Investment: $7,250,000
Timetable: The expansion will be completed in phases over the coming months and is expected to yield a maximum capacity of 800,000 Revogene^® PIEs per month by the end of calendar year 2021.

Company Need:
Meridian Bioscience, Inc. sought to increase production capacity of the company’s SARS-CoV-2 molecular diagnostic test on its Revogene^® platform.

Testimonial:

“We are excited to be in the final stages of bringing the Revogene SARS-CoV-2 assay to market. Our customers continue to search for more tests to battle this wave of the coronavirus pandemic and this support from our federal, state, and local governments will be instrumental in scaling our manufacturing capacity.”

— Tony Serafini-Lamanna, executive vice president of Diagnostics, Meridian Bioscience

Why Ohio?
Meridian will expand production of its Revogene^® test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near its corporate headquarters in the village of Newtown near Cincinnati.

Ohio’s healthcare industry has commanded worldwide attention for the innovative treatments developed in fields including heart disease, cancer, and pediatrics. Innovations in gene therapy at Nationwide Children’s Hospital in Columbus, cardiac care at the Cleveland Clinic, and pediatric care at Cincinnati Children’s Hospital are contributing to a sector that is attracting world-class researchers, entrepreneurs and investors.

Meridian received a $5.5M award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio. NIH launched the RADxSM initiative to speed innovation in developing, commercializing, and implementing technologies for COVID-19 testing.

CLICK HERE to read the release.

Collaborators:
JobsOhio, REDI Cincinnati, the village of Newtown, and the National Institutes of Health

Categories: Healthcare